JP2018514550A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018514550A5 JP2018514550A5 JP2017556651A JP2017556651A JP2018514550A5 JP 2018514550 A5 JP2018514550 A5 JP 2018514550A5 JP 2017556651 A JP2017556651 A JP 2017556651A JP 2017556651 A JP2017556651 A JP 2017556651A JP 2018514550 A5 JP2018514550 A5 JP 2018514550A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- ctla
- antibody according
- administered
- weeks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 5
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 5
- 201000001441 melanoma Diseases 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 230000037396 body weight Effects 0.000 claims 3
- 238000005259 measurement Methods 0.000 claims 3
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 1
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 238000011156 evaluation Methods 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 102000043321 human CTLA4 Human genes 0.000 claims 1
- 102000048362 human PDCD1 Human genes 0.000 claims 1
- 210000004969 inflammatory cell Anatomy 0.000 claims 1
- 229960005386 ipilimumab Drugs 0.000 claims 1
- 230000007774 longterm Effects 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 239000012188 paraffin wax Substances 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 229950007217 tremelimumab Drugs 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021037367A JP2021105000A (ja) | 2015-04-28 | 2021-03-09 | 抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体を使用するｐｄ−ｌ１陰性黒色腫の処置 |
| JP2024018579A JP2024063023A (ja) | 2015-04-28 | 2024-02-09 | 抗ｐｄ－１抗体および抗ｃｔｌａ－４抗体を使用するｐｄ－ｌ１陰性黒色腫の処置 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562153973P | 2015-04-28 | 2015-04-28 | |
| US62/153,973 | 2015-04-28 | ||
| PCT/US2016/029877 WO2016176503A1 (en) | 2015-04-28 | 2016-04-28 | Treatment of pd-l1-negative melanoma using an anti-pd-1 antibody and an anti-ctla-4 antibody |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021037367A Division JP2021105000A (ja) | 2015-04-28 | 2021-03-09 | 抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体を使用するｐｄ−ｌ１陰性黒色腫の処置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018514550A JP2018514550A (ja) | 2018-06-07 |
| JP2018514550A5 true JP2018514550A5 (enExample) | 2019-06-13 |
Family
ID=56087499
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017556651A Pending JP2018514550A (ja) | 2015-04-28 | 2016-04-28 | 抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体を使用するｐｄ−ｌ１陰性黒色腫の処置 |
| JP2021037367A Pending JP2021105000A (ja) | 2015-04-28 | 2021-03-09 | 抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体を使用するｐｄ−ｌ１陰性黒色腫の処置 |
| JP2024018579A Pending JP2024063023A (ja) | 2015-04-28 | 2024-02-09 | 抗ｐｄ－１抗体および抗ｃｔｌａ－４抗体を使用するｐｄ－ｌ１陰性黒色腫の処置 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021037367A Pending JP2021105000A (ja) | 2015-04-28 | 2021-03-09 | 抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体を使用するｐｄ−ｌ１陰性黒色腫の処置 |
| JP2024018579A Pending JP2024063023A (ja) | 2015-04-28 | 2024-02-09 | 抗ｐｄ－１抗体および抗ｃｔｌａ－４抗体を使用するｐｄ－ｌ１陰性黒色腫の処置 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US10174113B2 (enExample) |
| EP (2) | EP3988571A1 (enExample) |
| JP (3) | JP2018514550A (enExample) |
| KR (2) | KR20170138555A (enExample) |
| WO (1) | WO2016176503A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL318221A (en) * | 2012-05-15 | 2025-03-01 | Bristol Myers Squibb Co | Cancer immunotherapy by disrupting PD–1/PD–L1 signaling |
| RS60753B1 (sr) * | 2015-04-17 | 2020-10-30 | Bristol Myers Squibb Co | Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba |
| US10174113B2 (en) | 2015-04-28 | 2019-01-08 | Bristol-Myers Squibb Company | Treatment of PD-L1-negative melanoma using an anti-PD-1 antibody and an anti-CTLA-4 antibody |
| US11078278B2 (en) * | 2015-05-29 | 2021-08-03 | Bristol-Myers Squibb Company | Treatment of renal cell carcinoma |
| US10513558B2 (en) | 2015-07-13 | 2019-12-24 | Cytomx Therapeutics, Inc. | Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof |
| AU2016305697B2 (en) | 2015-08-11 | 2023-02-02 | WuXi Biologics Ireland Limited | Novel anti-PD-1 antibodies |
| CA2993432A1 (en) | 2015-09-01 | 2017-03-09 | Agenus Inc. | Anti-pd-1 antibodies and methods of use thereof |
| EP3532504A1 (en) * | 2016-10-28 | 2019-09-04 | Bristol-Myers Squibb Company | Methods of treating urothelial carcinoma using an anti-pd-1 antibody |
| BR112019011582A2 (pt) | 2016-12-07 | 2019-10-22 | Agenus Inc. | anticorpos e métodos de utilização dos mesmos |
| US20200102618A1 (en) * | 2017-03-17 | 2020-04-02 | Nantomics, Llc | LIQUID BIOPSY FOR cfRNA |
| WO2018183408A1 (en) * | 2017-03-31 | 2018-10-04 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer with a combination of an antagonist of pd-1 and an anti-ctla4 antibody |
| CA3063201A1 (en) * | 2017-05-09 | 2018-11-15 | Tesaro, Inc. | Combination therapies for treating cancer |
| CN110913911A (zh) | 2017-05-18 | 2020-03-24 | 特沙诺有限公司 | 用于治疗癌症的组合疗法 |
| CA3060618A1 (en) | 2017-05-19 | 2018-11-22 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel monoclonal antibodies to cytotoxic t-lymphocyte-associated protein 4 (ctla-4) |
| EP3697442A4 (en) | 2017-09-30 | 2021-07-07 | Tesaro, Inc. | COMBINATION THERAPIES FOR TREATMENT OF CANCER |
| EA202090655A1 (ru) | 2017-10-06 | 2020-12-07 | Тесаро, Инк. | Комбинированные терапевтические средства и их применение |
| US20210170025A1 (en) * | 2017-11-27 | 2021-06-10 | Heat Biologics, Inc. | Gp96-based cancer therapy |
| CA3089768A1 (en) | 2018-02-02 | 2019-08-08 | Oncoimmune, Inc. | Mutant anti-ctla-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects |
| CA3122773A1 (en) | 2018-12-26 | 2020-07-02 | Xilio Development, Inc. | Anti-ctla4 antibodies and methods of use thereof |
| CN114173794A (zh) * | 2019-06-25 | 2022-03-11 | 希望之城 | Pdl1阳性nk细胞癌症治疗 |
| GB201912107D0 (en) | 2019-08-22 | 2019-10-09 | Amazentis Sa | Combination |
| US20230277669A1 (en) | 2022-02-24 | 2023-09-07 | Amazentis Sa | Uses of urolithins |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| HU228477B1 (en) | 1999-08-23 | 2013-03-28 | Dana Farber Cancer Inst Inc | Pd-1, a receptor for b7-4, and uses therefor |
| CA2589418A1 (en) | 1999-08-24 | 2001-03-01 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| WO2001054732A1 (en) | 2000-01-27 | 2001-08-02 | Genetics Institute, Llc. | Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof |
| ES2350687T3 (es) | 2002-07-03 | 2011-01-26 | Ono Pharmaceutical Co., Ltd. | Composiciones de inmunopotenciación. |
| CA2508660C (en) | 2002-12-23 | 2013-08-20 | Wyeth | Antibodies against pd-1 and uses therefor |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| PL1907424T3 (pl) | 2005-07-01 | 2015-12-31 | Squibb & Sons Llc | Ludzkie monoklonalne przeciwciała wobec liganda zaprogramowanej śmierci 1 (PD-L1) |
| CA2647282A1 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| US8354509B2 (en) | 2007-06-18 | 2013-01-15 | Msd Oss B.V. | Antibodies to human programmed death receptor PD-1 |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| EA201500417A1 (ru) | 2008-08-25 | 2015-11-30 | Эмплиммьюн, Инк. | Композиции антагонистов pd-1 и способы применения |
| RU2017132160A (ru) | 2008-12-09 | 2019-02-08 | Дженентек, Инк. | Антитела к pd-l1 и их применение для усиления функции t-клеток |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| CA2828940C (en) | 2011-03-10 | 2024-04-16 | Provectus Pharmaceuticals, Inc. | Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer |
| EP2718508B1 (en) | 2011-04-18 | 2018-01-10 | Concentric Rockford Inc. | Velocity control for hydraulic control system |
| EP2699264B1 (en) | 2011-04-20 | 2018-03-14 | Medlmmune, LLC | Antibodies and other molecules that bind b7-h1 and pd-1 |
| BR112013032552A2 (pt) | 2011-07-24 | 2017-12-12 | Curetech Ltd | variantes de anticorpos monoclonais humanizados imunomoduladores |
| IL318221A (en) * | 2012-05-15 | 2025-03-01 | Bristol Myers Squibb Co | Cancer immunotherapy by disrupting PD–1/PD–L1 signaling |
| SMT201700540T1 (it) | 2012-10-02 | 2018-01-11 | Bristol Myers Squibb Co | Combinazione di anticorpi anti-kir e di anticorpi anti-pd-1 per il trattamento del cancro |
| EP3044234B9 (en) | 2013-09-13 | 2020-08-26 | BeiGene Switzerland GmbH | Anti-pd1 antibodies and their use as therapeutics and diagnostics |
| ES2728578T3 (es) | 2013-09-20 | 2019-10-25 | Bristol Myers Squibb Co | Combinación de anticuerpos anti-LAG-3 y anticuerpos anti-PD-1 para tratar tumores |
| MA40344A (fr) | 2014-07-18 | 2016-01-21 | Advaxis Inc | Combinaison d'un antagoniste de pd-1 et d'un vaccin à base de listeria pour le traitement du cancer |
| US10174113B2 (en) * | 2015-04-28 | 2019-01-08 | Bristol-Myers Squibb Company | Treatment of PD-L1-negative melanoma using an anti-PD-1 antibody and an anti-CTLA-4 antibody |
| KR20250107941A (ko) | 2015-04-28 | 2025-07-14 | 브리스톨-마이어스 스큅 컴퍼니 | 항-pd-1 항체를 사용한 pd-l1-양성 흑색종의 치료 |
-
2016
- 2016-04-28 US US15/141,769 patent/US10174113B2/en active Active
- 2016-04-28 EP EP21198377.0A patent/EP3988571A1/en active Pending
- 2016-04-28 JP JP2017556651A patent/JP2018514550A/ja active Pending
- 2016-04-28 KR KR1020177033882A patent/KR20170138555A/ko not_active Ceased
- 2016-04-28 KR KR1020247032661A patent/KR20240149980A/ko active Pending
- 2016-04-28 WO PCT/US2016/029877 patent/WO2016176503A1/en not_active Ceased
- 2016-04-28 EP EP16725959.7A patent/EP3288982A1/en not_active Withdrawn
-
2019
- 2019-01-04 US US16/240,316 patent/US20190194328A1/en not_active Abandoned
-
2021
- 2021-03-09 JP JP2021037367A patent/JP2021105000A/ja active Pending
- 2021-11-10 US US17/523,702 patent/US20220135685A1/en active Pending
-
2024
- 2024-02-09 JP JP2024018579A patent/JP2024063023A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018514550A5 (enExample) | ||
| JP2018515474A5 (enExample) | ||
| US20250154257A1 (en) | Treatment of lung cancer using a combination of an anti-pd-1 antibody and an anti-ctla-4 antibody | |
| CN105492016B (zh) | 脑信号蛋白-4d抑制分子与免疫调节治疗联用以抑制肿瘤生长和转移的应用 | |
| JP2023159353A (ja) | Ｔ細胞疲弊を予防および逆転するためのエピジェネティック標的および転写標的の同定 | |
| RU2017116847A (ru) | Антитела к pd-1 | |
| JP2018522887A5 (enExample) | ||
| JP2018520657A5 (enExample) | ||
| MX2024013016A (es) | Anticuerpos anti-pd1 para usarse en el tratamiento del cancer | |
| CN107750167A (zh) | 用于治疗癌症和感染的免疫检查点调节剂的抑制剂 | |
| JP2018501197A5 (enExample) | ||
| RU2018108048A (ru) | Новые анти-pd-1 антитела | |
| RS64268B1 (sr) | Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora | |
| Faleiro et al. | Combined immune therapy for the treatment of visceral leishmaniasis | |
| KR20190008962A (ko) | 림프종 치료에서의 항-cd30 항체와 조합된 항-pd-1 항체의 용도 | |
| KR20190026843A (ko) | Tim-4 길항제 및 pd-1 길항제의 조합물 및 사용 방법 | |
| JP2019503387A5 (enExample) | ||
| WO2018112407A1 (en) | Antibodies and methods for depleting regulatory b10 cells and use in combination with immune checkpoint inhibitors | |
| RS64388B1 (sr) | Pd-1 blokada nivolumabom kod refraktornog hočkinovog limfoma | |
| AU2019221672A1 (en) | Selective BCL-2 inhibitors in combination with an anti-PD- 1 or an anti-PD-L1 antibody for the treatment of cancers | |
| EP3743109A2 (en) | Mica/b antibodies and methods of use | |
| KR20180109977A (ko) | Il-17c에 대한 항체 | |
| JP2019534251A (ja) | Ｍｅｋ阻害剤、ｐｄ−１軸阻害剤、及びタキサンを用いた併用療法 | |
| WO2023034963A2 (en) | Combinations of immunotherapies and uses thereof | |
| JP2018516877A5 (enExample) |